Immune cell screening of a nanoparticle library improves atherosclerosis therapy.

ABSTRACT: Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe^-/-) mouse model of atherosclerosis, we quantitatively evaluated the li

SUBMITTER: Tang J 

PROVIDER: S-EPMC5098679 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature